The historical rank and industry rank for WAVE Life Sciences's PB Ratio or its related term are showing as below:
WVE'
s PB Ratio Range Over the Past 10 Years
Min: 1.4 Med: 6.1 Max: 30.1
Current: 7
During the past 12 years, WAVE Life Sciences's highest PB Ratio was 30.10. The lowest was 1.40. And the median was 6.10.
WVE's PB Ratio is ranked worse than 83.01% of 1283
companies
in the Biotechnology industry
Industry Median: 2.4
vs WVE: 7.00
During the past 12 months, WAVE Life Sciences's average Book Value Per Share Growth Rate was 311.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 36.10% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of WAVE Life Sciences was 36.10% per year. The lowest was -41.90% per year. And the median was -30.85% per year.
Back to Basics: PB Ratio
WAVE Life Sciences PB Ratio Historical Data
The historical data trend for WAVE Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WAVE Life Sciences's PB Ratio
For the Biotechnology subindustry, WAVE Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's PB Ratio falls into.
WAVE Life Sciences PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
WAVE Life Sciences PB Ratio Related Terms
Thank you for viewing the detailed overview of WAVE Life Sciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WVE has been successfully added to your 